Helix BioPharma Corp. (TSX:HBP)
Canada · Delayed Price · Currency is CAD 1.830
-0.260 (-12.44%)
Jan 22, 2026, 3:58 PM EST
Helix BioPharma Employees
Helix BioPharma had 7 employees as of July 31, 2024. The number of employees decreased by 2 or -22.22% compared to the previous year.
Employees
7
Change (1Y)
-2
Growth (1Y)
-22.22%
Revenue / Employee
n/a
Profits / Employee
-696.71K CAD
Market Cap
159.63M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jul 31, 2024 | 7 | -2 | -22.22% |
| Jul 31, 2023 | 9 | 2 | 28.57% |
| Jul 31, 2022 | 7 | -3 | -30.00% |
| Jul 31, 2021 | 10 | -1 | -4.76% |
| Jul 31, 2020 | 11 | -8 | -41.67% |
| Jul 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Extendicare | 23,000 |
| Sienna Senior Living | 12,263 |
| dentalcorp Holdings | 10,200 |
| Trulieve Cannabis | 6,000 |
| Curaleaf Holdings | 5,519 |
| Green Thumb Industries | 4,800 |
| WELL Health Technologies | 1,507 |
| Vireo Growth | 520 |
Helix BioPharma News
- 5 weeks ago - Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025 - TheNewswire
- 3 months ago - Helix Biopharma GAAP EPS of -$0.09 - Seeking Alpha
- 3 months ago - Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results - TheNewswire
- 3 months ago - Helix BioPharma Responds to Market Activity - TheNewswire
- 4 months ago - Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025 - TheNewswire
- 4 months ago - Helix BioPharma Concludes Review, Will Not Proceed with Proposed Equity Draw-Down Subscription Facility with GEM - TheNewswire
- 5 months ago - Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting - TheNewswire
- 5 months ago - Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC - TheNewswire